In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance Belapectin was overall well tolerated with no safety signals; incidence... Read More

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical... Read More

NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past... Read More

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual... Read More

NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright MASH Investor Conference being held October 7, 2024. Dr. Jamil will be sharing the latest updates on clinical programs and... Read More

NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26 th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Dr. Jamil will be providing a... Read More

NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We... Read More

NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are very... Read More

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc . (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. “At this year’s meeting we are again pleased to share important scientific information with the hepatology community.... Read More

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the... Read More

NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference. Detailed information about the presentation is below. H.C. Wainwright 2 nd Annual BioConnect Investor Conference Format: Fireside chat Date... Read More

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosis Fifth positive recommendation further supports favorable tolerability and safety profile of belapectin Interim Phase 2b efficacy readout anticipated in Q4 2024 NORCROSS, Ga., April 09, 2024 (GLOBE... Read More

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated... Read More

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. “We are pleased to welcome Khurram to the... Read More

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is... Read More

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertension and liver cirrhosis Clinical significance and interpretation of serum galectin-3 levels in patients with advanced liver disease Impact of... Read More

NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday,... Read More

NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors. Dr. Carson has served as a senior advisor to Galectin Therapeutics since 2021. In this role, he has increased awareness of Galectin’s ongoing Phase 2b/3... Read More

NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis.... Read More

NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20 th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and... Read More

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York –... Read More

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9 th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research... Read More

NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is... Read More

NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is... Read More

NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Investment Conference on Tuesday, May 2, 2023. Mr. Joel Lewis, Chief Executive Officer and President, and Dr. Pol F. Boudes, Chief Medical Officer, will participate in a fireside... Read More

NORCROSS, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management , sponsored by the American Association for the Study of Liver Diseases (AASLD). The Conference took place in Los Angeles, March 25-26, 2023. The AASLD has created a new... Read More

NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at... Read More

NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its third data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first... Read More

NORCROSS, Ga., March 02, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The last patient was randomized into... Read More

NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics , a prominent peer-reviewed... Read More

NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first study of its kind and is a global... Read More

Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertension Biochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertension Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inflammatory Marker Clinical utility of the ELF score in compensated NASH cirrhotic patients with portal hypertension Histological correlation with... Read More

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October 17, 2022, management will present in the H.C. Wainwright 6th Annual NASH Investor Conference. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Monday, October 17, 2022 at... Read More

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug (IND) application for belapectin in combination with a checkpoint inhibitor for the treatment of Head and Neck cancer has been filed with the U.S. Food and Drug Administration (FDA) Oncology division. Galectin Therapeutics also received a Study May Proceed letter for a... Read More

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its second data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first study of its kind and is a global effort that... Read More

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and... Read More

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov . Joel Lewis, Chief Executive... Read More

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chairman and largest individual stockholder, Richard E. Uihlein. “It has been close to fifteen years since I made my first investment in Galectin Therapeutics,” said Richard E. Uihlein, chairman of the board of directors. “While... Read More

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today two scientific presentations regarding the use of artificial intelligence to analyze liver biopsies of patients affected with cirrhosis of the liver due to Nonalcoholic Steatohepatitis (NASH). The data originates from the Company’s phase 2 study (NCT02462967) that evaluated its proprietary drug candidate... Read More